IGC Fundamental Analysis - IGC PHARMA INC

Fundamental Rating

IGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. IGC may be in some trouble as it scores bad on both profitability and health. IGC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IGC has reported negative net income.

In the past year IGC has reported a negative cash flow from operations.

IGC had negative earnings in each of the past 5 years.

In the past 5 years IGC always reported negative operating cash flow.

1.2 Ratios

IGC has a worse Return On Assets (-66.16%) than 67.71% of its industry peers.

With a Return On Equity value of -79.66%, IGC perfoms like the industry average, outperforming 43.75% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-66.16%
ROE	-79.66%
ROIC	N/A

ROA(3y)-93.23%

ROA(5y)-72.05%

ROE(3y)-122.42%

ROE(5y)-91.4%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of IGC (46.20%) is better than 61.98% of its industry peers.

In the last couple of years the Gross Margin of IGC has grown nicely.

IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	46.2%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.84%

GM growth 5Y75.22%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.

IGC has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, IGC has more shares outstanding

IGC has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -9.82, we must say that IGC is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -9.82, IGC is doing worse than 70.83% of the companies in the same industry.

IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.02, IGC is in line with its industry, outperforming 56.25% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	-9.82

ROIC/WACCN/A

WACC9.05%

2.3 Liquidity

A Current Ratio of 1.32 indicates that IGC should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.32, IGC is doing worse than 74.48% of the companies in the same industry.

IGC has a Quick Ratio of 1.32. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.89, IGC is not doing good in the industry: 80.21% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.32
Quick Ratio	0.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.49%, which is quite impressive.

The Revenue has decreased by -6.51% in the past year.

Measured over the past years, IGC shows a very negative growth in Revenue. The Revenue has been decreasing by -20.77% on average per year.

EPS 1Y (TTM)58.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.06%

Revenue 1Y (TTM)-6.51%

Revenue growth 3Y47.02%

Revenue growth 5Y-20.77%

Sales Q2Q%-53.64%

3.2 Future

The Earnings Per Share is expected to grow by 10.20% on average over the next years. This is quite good.

IGC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.74% yearly.

EPS Next Y30.18%

EPS Next 2Y10.2%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year4.61%

Revenue Next 2Y9.74%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.2%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IGC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IGC PHARMA INC

NYSEARCA:IGC (12/3/2025, 8:04:00 PM)

After market: 0.3099 +0.01 (+2.62%)

0.302

0 (-1.31%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-17 2025-11-17/bmo

Earnings (Next)02-12 2026-02-12

Inst Owners18.55%

Inst Owner ChangeN/A

Ins Owners3.95%

Ins Owner Change-0.66%

Market Cap28.05M

Revenue(TTM)1.11M

Net Income(TTM)-6.45M

Analysts80

Price Target3.7 (1125.17%)

Short Float %0.29%

Short Ratio0.33

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-21.1%

Min Revenue beat(2)-41.81%

Max Revenue beat(2)-0.38%

Revenue beat(4)2

Avg Revenue beat(4)-8.52%

Min Revenue beat(4)-41.81%

Max Revenue beat(4)7.13%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-6.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)35.39%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)5.52%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-10.17%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	25.36
P/FCF	N/A
P/OCF	N/A
P/B	3.47
P/tB	8.73
EV/EBITDA	N/A

EPS(TTM)-0.08

EYN/A

EPS(NY)-0.07

Fwd EYN/A

FCF(TTM)-0.07

FCFYN/A

OCF(TTM)-0.06

OCFYN/A

SpS0.01

BVpS0.09

TBVpS0.03

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.16%
ROE	-79.66%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	46.2%
FCFM	N/A

ROA(3y)-93.23%

ROA(5y)-72.05%

ROE(3y)-122.42%

ROE(5y)-91.4%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.84%

GM growth 5Y75.22%

F-Score2

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	125.74%
Cap/Sales	64.92%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.32
Quick Ratio	0.89
Altman-Z	-9.82

F-Score2

WACC9.05%

ROIC/WACCN/A

Cap/Depr(3y)84.26%

Cap/Depr(5y)139.57%

Cap/Sales(3y)48.11%

Cap/Sales(5y)101.2%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)58.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.06%

EPS Next Y30.18%

EPS Next 2Y10.2%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-6.51%

Revenue growth 3Y47.02%

Revenue growth 5Y-20.77%

Sales Q2Q%-53.64%

Revenue Next Year4.61%

Revenue Next 2Y9.74%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y5.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y9.51%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y11.44%

OCF growth 3YN/A

OCF growth 5YN/A

IGC PHARMA INC / IGC FAQ

What is the fundamental rating for IGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IGC.

What is the valuation status for IGC stock?

ChartMill assigns a valuation rating of 0 / 10 to IGC PHARMA INC (IGC). This can be considered as Overvalued.

Can you provide the profitability details for IGC PHARMA INC?

IGC PHARMA INC (IGC) has a profitability rating of 1 / 10.

What is the expected EPS growth for IGC PHARMA INC (IGC) stock?

The Earnings per Share (EPS) of IGC PHARMA INC (IGC) is expected to grow by 30.18% in the next year.

IGC PHARMA INC (IGC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

IGC PHARMA INC / IGC FAQ

What is the fundamental rating for IGC stock?

What is the valuation status for IGC stock?

Can you provide the profitability details for IGC PHARMA INC?

What is the expected EPS growth for IGC PHARMA INC (IGC) stock?